Gilead Sciences, Inc. (NASDAQ:GILD – Get Free Report)’s share price reached a new 52-week high during mid-day trading on Wednesday following a better than expected earnings announcement. The company ...

Andrew Dickinson, the Chief Financial Officer of Gilead Sciences, Inc. (NASDAQ:GILD), recently executed a series of transactions involving the company's stock. On February 12, Dickinson sold 137,676 ...

Robinhood reported fourth-quarter revenue of $1.01 billion, up 115% year-over-year and a new company record. The revenue ...

BofA raised the firm’s price target on Gilead (GILD) to $116 from $109 and keeps a Buy rating on the shares. Q4 results “handily beat ...

U.S. investors and large pharmaceutical companies are increasingly doing deals in China as the country’s biopharma sector ...

Ideaya Biosciences (IDYA) announced it has entered into an additional clinical study collaboration and supply agreement with Gilead Sciences ...

Most U.S. stocks fell Wednesday after a report showed inflation is unexpectedly worsening for Americans. The S&P 500 dropped 0.3%, though it had been on track for a much worse loss of 1.1% at the ...

NEW YORK — Most U.S. stocks fell Wednesday after a report showed inflation is unexpectedly worsening for Americans. The ...

U.S. stocks mostly fell as inflation worsens, with the S&P 500 down 0.3% and the Dow dropping 225 points. Inflation pressures ...

Shares of Gilead Sciences Inc. advanced 7.46% to $103.31 Wednesday, on what proved to be an all-around poor trading session ...

The S&P 500 dropped 0.3% on Wednesday, Feb. 12, as hotter-than-expected inflation data in the January CPI report weighed on the interest rate outlook.